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Purpose: Human epidermal growth factor receptor 2 (HER2)/neu, topoisomerase II alpha 
(TOP2A), and polysomy 17 may predict tumor responsiveness to doxorubicin (DOX) 
therapy.
Methods: We identified neoadjuvant DOX/cyclophosphamide treated breast cancer patients in 
our registry from 1997 to 2008 with sufficient tissue for testing (n = 34). Fluorescence in situ 
hybridization (FISH) testing was done on deparaffinized tissue sections pretreated using vendor’s 
standard protocol modification, and incubated with US Food and Drug Administration approved 
Abbott Diagnostics Vysis PathVysion probe set, including Spectrum-Green-conjugated 
probe to α-satellite DNA located at the centromere of chromosome 17 (17p11.1–q11.1) and a 
Spectrum-Orange-conjugated probe to the TOP2A gene. Morphometric analysis was performed 
using a MetaSystems image analysis system. Manual counting was performed on all samples 
in which autofluorescence and/or artifact prevented the counting of sufficient numbers of cells. 
A ratio .2.0 was considered positive for TOP2A amplification. Polysomy 17 (PS17) presence 
was defined as signals of $2.5. Outcomes were pathological complete response (pCR), partial 
response (PR), and nonresponse (NR).
Results: Of 34 patients tested, one was TOP2A amplified (hormone receptor negative/HER2 
  negative, partial responder). The subset of TOP2A nonamplified, HER2 negative, and PS17 
absent (n = 23) patients had treatment response: pCR = 2 (9%), PR = 14 (61%), and NR = 7 
(30%). Including the two PS17 present and HER2-positive patients (n = 33), 76% of TOP2A 
nonamplified patients had pCR or PR.
Conclusions: We observed substantial treatment response in patients lacking three postulated 
predictors that would be difficult to attribute to cyclophosphamide alone. Patients who are 
HER2 negative and lack TOP2A amplification and PS17 should not be excluded from receiving 
DOX-containing regimens.
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Introduction
Recent reports have proposed topoisomerase II alpha (TOP2A) biomarker status as 
a potential predictor of tumor responsiveness to doxorubicin (DOX) therapy.1 These 
studies predominantly evaluated relapse-free survival in the adjuvant setting related 
to human epidermal growth factor receptor 2 (HER2)-neu and TOP2A status although 





Contradictory results have been reported for anthracycline 
response among HER2 amplified tumors, although in 
general anthracycline responsiveness has been correlated 
with HER2 positivity.7,8 Konecny et al1 have correlated 
anthracycline responsiveness with TOP2A amplification 
and deletion, though again there is no unanimity regard-
ing this observation. Paradoxically, favorable response to 
anthracyline therapy, especially in the neoadjuvant setting, 
has been observed in patients with triple-negative breast 
cancer.9
The TOP2A gene product is a target of anthracyclines, 
and the gene is located in chromosome 17 (17q21–22) in 
close proximity to HER2. Polysomy 17 (PS17) has also been 
proposed as a predictive marker for anthracycline sensitiv-
ity although there is far less data available regarding this 
observation.8 Our study aim is to evaluate tumor response in 
a retrospective cohort of breast cancer patients treated with 
neoadjuvant DOX and cyclophosphamide (C) in relation to 
HER2, topoisomerase II, and PS17 expression.
Materials and methods
We retrospectively identified all breast cancer patients in 
our community-based cancer clinic registry cohort treated 
with neoadjuvant DOX and cyclophosphamide (C) only 
prior to surgery. Hormone receptor (HR) and HER2 testing 
were completed as part of their initial clinical evaluation. 
Forty-five patients in our patient registry had neoadjuvant 
DOX/C treatment and were given no other neoadjuvant 
therapy. Thirty-four of these patients had sufficient tissue 
available for testing and adequate signal for measurement of 
TOP2A gene amplification. Choice of neoadjuvant treatment 
drug and number of cycles to be delivered was made by the 
treating physician.
Estrogen receptor and progesterone receptor status were 
assessed by immunohistochemistry (IHC) at various local 
laboratories; HER2 status was assessed by either IHC or 
fluorescent in situ hybridization (FISH) or both in the case 
of an equivocal IHC result (FISH). Breast biopsy tissue was 
preserved in paraffin blocks and stored at room temperature 
prior to testing. FISH testing was done on deparaffinized tis-
sue sections pretreated using a modification of the vendor’s 
standard protocol, and then incubated with the US Food and 
Drug Administration-approved Vysis PathVysion probe 
set, which includes Spectrum-Green-conjugated probe to the 
α-satellite DNA located at the centromere of chromosome 17 
(17p11.1–q11.1) and a Spectrum-Orange-conjugated probe 
to the TOP2A gene (Abbott Diagnostics, Chicago, IL, USA). 
For every batch of tumor sections, appropriate quality control 
sections were used for FISH testing. Morphometric analysis 
was performed using a MetaSystems image analysis system, 
incorporating the Metafer software with extended focus/
tile sampling methodology (MetaSystems, Altlussheim, 
Germany). Manual counting was performed on all samples 
in which autofluorescence and/or artifact prevented the 
counting of sufficient numbers of cells. A ratio .2.0 is con-
sidered positive for TOP2A amplification. PS17 presence 
was defined as signal of $2.5. Figure 1 illustrates TOP2A 
present amplification.
Pretreatment tumor size was determined by imaging 
and physical examination and posttreatment size was 
determined from the pathological specimen and the 
pathologist’s report with response measured postsurgery 
after receipt of DOX/C neoadjuvant therapy. The clinical 
end point was response to treatment and was measured as 
pathological complete response (pCR), partial response 
(PR), and nonresponse (NR) using RECIST criteria.10 
Response was assigned after surgery and pCR was 
assigned if there was no residual disease in the breast 
tissue or lymph nodes. PR was assigned if there was 
evidence of 30% or greater decrease in tumor size (PR) 
and no response (NR) if the tumor size reduction was 
less than 30%.
Statistical analysis was done using SPSS 17.0 software 
for univariate and bivariate analysis.11 Pearson chi-square   
tests were done to identify significant differences between 
groups using a 2-sided test for probability using the Fisher’s 
Exact test for small number comparisons.
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Results
The 34 patients tested for TOP2A were diagnosed between 
1997 and 2008 with TNM stage II-IV breast cancer and 
were treated with neoadjuvant DOX and cyclophosph-
amide. Patients’ age range was 29–66 years with a mean 
of 46.47 and a median age of 46. Seventy-six percent of 
the patients had clinically positive lymph node status. 
Clinical tumor size at the time of diagnosis was 1.6–11.0 
cm with 5/34 (14.7%) equal to 1.6–2.5 cm, a mean of 6.13 
cm and median of 6.0 cm. The most common histologic 
type was ductal carcinoma (79%) with 88% exhibiting high 
histologic grade and 71% with high nuclear grade. Out of 
34 patients tested for topoisomerase II, one was TOP2A 
amplified (HR−/HER2−, partial responder). A total of 18 
out of 34 were HR+ and 9 were HER2+. Data are presented 
in Table 1.
Twenty-four of the 34 patients were treated with 4 cycles 
of DOX/C, 3 of 34 had 5 cycles of DOX/C, and 4 of 34 had 
6 cycles of DOX/C. One of 34 patients had 2 cycles and 1/34 
had 3 cycles. One of the 34 patients had a weekly treatment 
protocol as part of a randomized clinical trial (RCT) receiv-
ing 15 weeks of DOX/C therapy. The 2 patients with less than 
4 cycles of therapy had early substantial reduction in tumor 
size (PR) and went to surgery. Descriptives are presented in 
Table 1.
Among the subset of TOP2A normal patients (n = 33), 
treatment response was pCR = 4 (12.1%), PR = 21 (63.6%), 
and NR = 8 (24.2%) with the majority (75.7%) exhibiting 
significant responsiveness (pCR or PR) to DOX/C. Distribu-
tion by HR and HER2 status and therapy response for the 
subset of TOP2A nonamplified/PS17 absent patients (n = 31) 
was (1) HR−/HER2− (n = 9), 22% pCR, 56% PR, 22% NR; 
(2) HR+/HER2− (n = 14), 64% PR, 36% NR; (3) HR−/
HER2+ (n = 6), 33% pCR, 67% PR; and (4) HR+/HER2+ 
(n = 2), 50% PR, 50% NR. For the subset of HER2 negative 
and TOP2A nonamplified patients (n = 24), the response 
rates were 8% pCR (2/24), 63% PR (15/24), and 29% NR 
(7/24). For the subset of HER2 negative, TOP2A nonampli-
fied and PS17 absent patients (n = 23), treatment response 
were pCR = 2 (9%), PR = 14 (61%), and NR = 7 (30%). See 
Table 2 and Figure 2 for summary.
When response to treatment was analyzed for all cases 
(n = 34) by HR and HER2 status, the best response was among 
the HR−/HER2+ patients with 100% partial or complete 
response followed by the triple-negative group with 80% 
partial or complete response (Pearson χ2 = 7.32, 6 degrees 
of freedom, P = 0.293; Table 3).
Table 1 Descriptors of patients tested for TOP2A (n = 34)
Variable N (%)
Age in years
  Range 29–66
  Mean 46.47
TnM stage
  ii 11 (32%)
  iii 19 (56%)
  iV 4 (12%)
Lymph node status
  negative 8 (24%)
  Positive 26 (76%)
Clinical tumor size, cm
  Range 1.6–11.0
  Mean 6.13
histologic type
  Ductal 27 (79%)
  Lobular 3 (9%)
  Other 4 (12%)
histologic grade
  intermediate 2 (9%)
  high 30 (88%)
nuclear grade
  Low to intermediate 9 (26%)
  intermediate 1 (3%)
  high 24 (71%)
  eR = positive 17 (50%)
  PR = positive 11 (32%)
  her2 = positive 9 (27%)
TOP2A
  normal 33 (97%)
  Amplified 1 (3%)
PS17
  not present 32 (94%)
  Present 2 (6%)
number of treatment cycles
  Weekly 1 (3%)
  ,4 2 (6%)
 4 24 (71%)
 5 3 (9%)
 6 4 (12%)
Abbreviations:  eR,  estrogen  receptor;  PR,  progesterone  receptor;  heR2, 
human epidermal growth factor receptor 2; TOP2A, topoisomerase II alpha; PS17, 
polysomy 17.
Table 2 summary of response to treatment by heR2 negative, 







N pCR, % PR, % NR, %
– Nonamplified – 33 12 64 24
– Nonamplified Absent 31 13 61 26
negative Nonamplified – 24 8 63 29
negative Nonamplified Absent 23 9 61 30
Abbreviations:  heR2,  human  epidermal  growth  factor  receptor  2;  TOP2A, 
topoisomerase ii alpha, pCR, pathological complete response; PR, partial response; 






Topoisomerase is a known target for anthracycline cyto-
toxicity and it has been proposed that alterations in TOP2A 
correlate with clinical antitumor activity making TOP2A a 
biomarker candidate for treatment selection decision making. 
This theory has been evaluated by retrospective review of 
TOP2A status and mortality outcomes of patients in random-
ized controlled trials (RCTs) and cohort studies, and response 
to treatment in neoadjuvant studies with mixed results in all 
three types of studies.5,9,10,12–14 Similarly, HER2 status has been 
correlated with anthracycline response to varying degrees, 
though reviews of the literature have led some investigators 
to conclude that anthracycline benefit may not be   predicted 
by HER2 or TOP2A status.15,16 Most recently, Bartlett et al8 
proposed that PS17 duplication (CH17CEP) is the   strongest 
  predictor of treatment benefit with   anthracyclines.8 They 
observe that the presence of HER2/TOP2A on   chromosome 
17 may explain the inconsistent results observed in regards 
to these biomarkers and anthracycline benefit.
To further assess these indicators, we reviewed the 
response of all patients who received neoadjuvant DOX/C 
alone at our institution. In particular, we examined the 
response of the patients in this group who lacked all three 
putative predictors of anthracycline responsiveness and also 
correlated response with HR status. The strength of our 
study is the use of neoadjuvant treatment tumor response as 
the outcome of interest instead of survival over time which 
has been the outcome measurement in RCT reviews. The 
weakness of our study is the absence of a sufficient number 
of TOP2A-amplified patients for a comparison group. It is 
and would be difficult to obtain a subset of TOP2A-amplified 
patients for the review of response to neoadjuvant therapy 
as neoadjuvant patients are more likely to be triple negative 
with a lower percentage of TOP2A amplification present. To 
assemble a suitably powerful cohort would require an initial 
sample size of approximately 200 patients not predominantly 
triple negative with at least 25% HER2 positive and 10% 
TOP2A-amplified patients (n = 20). A sample size of this 
magnitude would allow for an adequate observational report, 
but to evaluate the net benefit of TOP2A as a biomarker with 
the capacity to advise treatment selection an RCT has prefer-
able strength. In lieu of these currently unobtainable options 
at our institution, we chose to conduct a study with results 
that can reassure clinicians of the effectiveness of anthra-
cycline therapy previously proven by RCTs and currently 
called into question by underpowered studies with indirect 
end points, ie, disease specific and all cause mortality.
Among topoisomerase II normal patients, response was 
substantial with a 76% combined complete and PR rate. 
Both pCR and overall response rates were highest among 
HR-negative patients when the 34 cases were compared 
with HR and HER2 status, though we were unable to com-
pare response with HR−/HER2+ nonresponders due to an 
absence of patients in that category. Patients who lacked 
HER-2/neu, PS17, and TOP2A amplification still exhibited 
a combined pCR/PR of 70% (pCR of 9%). By comparison, 
TOP2A-amplified patients had zero response to neoadju-
vant therapy (n = 3) in the study by Kawachi et al3 from 
a total sample of 14 patients and a pCR of 60% (3/5) was 
observed in TOP2A-amplified tumors that were estrogen and 
Table 3 Response to treatment by hormone receptor and heR2 





N pCR, % PR, % NR, %
negative negative 10 20 60 20
Positive negative 15 0 67 33
negative Positive 6 33 67 0
Positive Positive 3 0 67 33
Total 34 12 65 24
aPearson χ2 = 7.32, 6 degrees of freedom, P = 0.293 (3 zero cells).
Abbreviations:  heR2,  human  epidermal  growth  factor  receptor  2;  pCR, 
pathological complete response; PR, partial response; nR, nonresponse.
Total of patients treated with  
neoadjuvant DOX/C (n = 45)
Neoadjuvant DOX/C patients with 
sufficient tissue for testing (n = 34)
Neoadjuvant DOX/C patients 
TOP2A Normal (n = 33)
Neoadjuvant DOX/C patients
TOP2A normal/Polysomy17 absent (n = 31)
Neoadjuvant DOX/C patients 
HER2 negative/TOP2A normal
(n = 24)
Neoadjuvant DOX/C patients 
HER2 negative/TOP2A normal/PS 17 absent
(n = 23)
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progesterone receptor negative and HER2 positive reported 
by Orlando et al5 from a total sample size of 23 patients. Both 
of these studies had fewer patients, n = 14 and n = 23, than 
our current study but had more TOP2A-amplified patients, 
n = 3 and n = 5, respectively.
Conclusions
Initial drug trials in the 1960s using single-agent cyclophos-
phamide showed a 27% PR rate in the treatment of metastatic 
breast cancer.17 Complete responses were rare. Although it 
may be possible that response rates for cyclophosphamide 
may be slightly higher than the rate of 27% reported from 
early trials, it is extremely unlikely that the partial and 
complete response rates observed in our patient population 
could be obtained by cyclophosphamide alone. Although a 
number of studies have suggested that HER2, TOP2A, and/
or PS17 amplification may predict response to DOX, we 
observed substantial response to treatment in patients lacking 
all 3 postulated predictors of therapy that would be difficult 
to attribute to cyclophosphamide alone. Our results indicate 
HR and HER2 status are dominant indicators of response in 
the absence of TOP2A and PS17 amplification. Our results 
replicate the observations of others that triple-negative breast 
cancer (HR−/HER2−) patients have a high response rate to 
anthracyclines.18 HER2-negative patients have previously 
been shown to have a very low incidence of TOP2A ampli-
fication or deletion so triple-negative patients likely lack 
TOP2A amplification or deletion as well.19
In general, there is a strong correlation between pCR 
from neoadjuvant chemotherapy and overall survival, but 
poor long-term survival has been observed in triple-negative 
disease despite positive response to initial therapy.18 Factors 
other than those examined here may be involved in the initial 
response to treatment and those factors may change during 
the natural history of the disease. Tenari et al20 has reported 
that TOP2A levels change over time and with treatment. 
Ejlertsen et al21 has recently reported a correlation between 
anthracycline responsiveness and tissue inhibitor of matrix 
metalloproteinases 1(TIMP1), suggesting another molecular 
target that requires further analysis.
We found a clear utility of anthracycline/cyclophosphamide 
combined therapy in a cohort of patients treated with neoadju-
vant therapy prior to surgery. Future studies may find a link or 
new marker that will correlate with and/or predict response to 
anthracycline therapy, but at this time there is insufficient evi-
dence to exclude patients from receiving anthracycline therapy 
based on HER2, TOP2A, and/or PS17 expression.
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